13F filer · CIK 1697748 ↗
ARK Invest
You are looking at Q2 2018. See the latest, Q2 2026 →
Reported value
$2.73B
+36% on the quarter before
Positions
200
13 new · 12 sold out
Top 10
38.8%
of the value
Est. gain
+$223.9M
on stocks held all quarter
Est. return
+12.1%
on those stocks since Q1 2018
Positions as of Jun 30, 2018, from ARK Invest's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2018. Striped tiles are options.
Largest buys
Since Q1 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Tesla~$44.1MAdded · 4.2% → 5.6%+128,497 shares
- Stratasys Ltd~$37.7MAdded · 4.8% → 4.8%+1,970,216 shares
- Teradyne~$35.6MAdded · 1.2% → 2.0%+934,612 shares
- Spotify Technology Sa~$34.0MNew · 0.0% → 1.2%+202,304 shares
- Apple~$32.1MAdded · 2.1% → 2.9%+173,553 shares
- TSMC~$25.4MAdded · 0.5% → 1.2%+694,064 shares
- Intellia Therapeutics Inc~$24.9MAdded · 3.8% → 4.5%+910,608 shares
- Microsoft~$23.7MAdded · 0.3% → 1.1%+240,612 shares
- Jd.Com Inc-ADR~$23.5MAdded · 2.3% → 2.5%+603,710 shares
- Crispr Therapeutics Ag~$23.2MAdded · 0.2% → 1.0%+394,606 shares
Largest sells
Since Q1 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- 2u Inc~$18.5MCut · 1.9% → 0.7%−221,715 shares
- Nintendo Co Ltd-Unspons ADR~$18.4MSold out · 0.9% → 0.0%−330,964 shares
- Autodesk~$17.5MCut · 1.0% → 0.2%−133,574 shares
- Meta~$17.3MCut · 1.2% → 0.5%−89,102 shares
- PayPal~$11.8MCut · 1.1% → 0.4%−142,011 shares
- Proto Labs Inc~$10.0MCut · 0.9% → 0.3%−83,712 shares
- Foundation Medicine Inc~$9.3MCut · 0.3% → 0.1%−67,701 shares
- Medidata Solutions Inc~$6.8MCut · 2.2% → 1.9%−84,229 shares
- Hortonworks Inc~$6.6MCut · 1.4% → 0.7%−362,966 shares
- Softbank Group Corp-Unsp ADR~$5.9MCut · 0.9% → 0.4%−164,886 shares
Holdings
As of Jun 30, 2018. Changes are in shares against Mar 31, 2018, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TeslaCommon Stock · shares +41% · price +28.9% | 5.6% | $152.2M | +$24.2M | ||||||||
| Stratasys LtdCommon Stock · shares +41% · price −5.2% | 4.8% | $130.3M | −$5.0M | ||||||||
| Intellia Therapeutics IncCommon Stock · shares +25% · price +29.7% | 4.5% | $123.5M | +$22.6M | ||||||||
| Twitter IncCommon Stock · shares +2.3% · price +50.5% | 4.4% | $120.4M | +$39.5M | ||||||||
| BaiduADR · shares +29% · price +8.9% | 3.7% | $100.9M | +$6.4M | ||||||||
| Illumina IncCommon Stock · shares +32% · price +18.1% | 3.4% | $93.0M | +$10.8M | ||||||||
| Athenahealth IncCommon Stock · shares +12% · price +11.3% | 3.2% | $87.4M | +$7.9M | ||||||||
| AmazonCommon Stock · shares −5.7% · price +17.4% | 3.2% | $87.3M | +$13.0M | ||||||||
| BlockCommon Stock · shares +25% · price +25.3% | 3.1% | $84.2M | +$13.6M | ||||||||
| AppleCommon Stock · shares +70% · price +10.3% | 2.9% | $78.3M | +$4.3M | ||||||||
| Editas Medicine IncCommon Stock · shares +35% · price +8.1% | 2.9% | $78.2M | +$4.3M | ||||||||
| NvidiaCommon Stock · shares +2.7% · price +2.3% | 2.7% | $73.8M | +$1.6M | ||||||||
| NetflixCommon Stock · shares −3.5% · price +32.5% | 2.6% | $69.8M | +$17.1M | ||||||||
| Jd.Com Inc-ADRADR · shares +52% · price −3.8% | 2.5% | $68.8M | −$1.8M | ||||||||
| Invitae CorpCommon Stock · shares +27% · price +56.7% | 2.4% | $64.8M | +$18.4M | ||||||||
| Lendingclub CorpCommon Stock · shares +30% · price +8.3% | 2.1% | $58.7M | +$3.5M | ||||||||
| Tencent Holdings Ltd-Uns ADRADR · shares +60% · price −5.7% | 2.1% | $56.3M | −$2.1M | ||||||||
| TeradyneCommon Stock · shares +176% · price −16.7% | 2.0% | $55.8M | −$4.1M | ||||||||
| Medidata Solutions IncCommon Stock · shares −12% · price +28.3% | 1.9% | $50.6M | +$11.1M | ||||||||
| SalesforceCommon Stock · shares +19% · price +17.3% | 1.8% | $50.2M | +$6.2M | ||||||||
| Xilinx IncCommon Stock · shares +32% · price −9.7% | 1.7% | $46.8M | −$3.8M | ||||||||
| Red Hat IncCommon Stock · shares +62% · price −10.1% | 1.7% | $46.0M | −$3.2M | ||||||||
| Bluebird Bio IncCommon Stock · shares +33% · price −8.1% | 1.5% | $41.3M | −$2.7M | ||||||||
| Aptiv PlcCommon Stock · shares +33% · price +7.8% | 1.5% | $39.7M | +$2.2M | ||||||||
| Cerus CorpCommon Stock · shares +8.4% · price +21.7% | 1.4% | $38.0M | +$6.2M | ||||||||
| Total · 200 positions | 100% | $2.73B | +$223.9M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2018 to Q2 2018: 187 stocks held throughout, up $223.9M (+12.1%).
- Twitter Inc+$39.5M+51%
- Tesla+$24.2M+29%
- Intellia Therapeutics Inc+$22.6M+30%
- Invitae Corp+$18.4M+57%
- Netflix+$17.1M+33%
- Xilinx Inc−$3.8M−10%
- Teradyne−$4.1M−17%
- Syros Pharmaceuticals Inc−$4.2M−21%
- Compugen Ltd−$4.6M−26%
- Stratasys Ltd−$5.0M−5%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $15.40B+20% | SEC ↗ |
| Q1 2026 | May 12, 2026 | $12.86B−15% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $15.07B−10% | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | $16.80B+23% | SEC ↗ |
| Q2 2025 | Jul 30, 2025 | $13.64B+37% | SEC ↗ |
| Q1 2025 | May 7, 2025 | $9.99B−17% | SEC ↗ |
| Q4 2024 | Feb 4, 2025 | $12.01B+10% | SEC ↗ |
| Q3 2024 | Oct 31, 2024 | $10.93B−3% | SEC ↗ |
| Q2 2024 | Jul 26, 2024 | $11.27B−22% | SEC ↗ |
| Q1 2024 | Apr 18, 2024 | $14.44B−14% | SEC ↗ |
| Q4 2023 | Jan 17, 2024 | $16.89B+29% | SEC ↗ |
| Q3 2023 | Oct 18, 2023 | $13.07B−13% | SEC ↗ |
| Q2 2023 | Jul 10, 2023 | $15.10B+4% | SEC ↗ |
| Q1 2023 | Apr 17, 2023 | $14.55B+26% | SEC ↗ |
| Q4 2022 | Jan 24, 2023 | $11.54B−20% | SEC ↗ |
| Q3 2022 | Oct 17, 2022 | $14.35B−15% | SEC ↗ |
| Q2 2022 | Jul 11, 2022 | $16.91B−29% | SEC ↗ |
| Q1 2022 | Apr 18, 2022 | $23.96B−28% | SEC ↗ |
| Q4 2021 | Jan 28, 2022 | $33.08B−21% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $41.64B−23% | SEC ↗ |
| Q2 2021 | Aug 5, 2021 | $53.74B+7% | SEC ↗ |
| Q1 2021 | May 13, 2021 | $50.34B+34% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $37.59B+123% | SEC ↗ |
| Q3 2020 | Oct 30, 2020 | $16.86B+81% | SEC ↗ |
| Q2 2020 | Aug 11, 2020 | $9.30B+132% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $4.01B+1% | SEC ↗ |
| Q4 2019 | Jan 31, 2020 | $3.96B−13% | SEC ↗ |
| Q3 2019 | Nov 12, 2019 | $4.58B+15% | SEC ↗ |
| Q2 2019 | Jul 30, 2019 | $3.97B+13% | SEC ↗ |
| Q1 2019 | May 13, 2019 | $3.50B+42% | SEC ↗ |
| Q4 2018 | Feb 11, 2019 (amended) | $2.46B−26% | SEC ↗ |
| Q3 2018 | Nov 7, 2018 | $3.31B+21% | SEC ↗ |
| Q2 2018 | Aug 7, 2018 | $2.73B+36% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $2.01B+60% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $1.26B+53% | SEC ↗ |
| Q3 2017 | Nov 9, 2017 | $819.3M+60% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $513.6M+48% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $346.9M+26% | SEC ↗ |
| Q4 2016 | Feb 13, 2017 | $274.9M | SEC ↗ |